BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8751562)

  • 1. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R; Jewett A; Bonavida B
    Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
    Uslu R; Bonavida B
    Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
    Morimoto H; Yonehara S; Bonavida B
    Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N; Belldegrun A; Bonavida B
    Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis.
    Garbán HJ; Bonavida B
    Gynecol Oncol; 1999 May; 73(2):257-64. PubMed ID: 10329044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
    Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
    Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
    Zhang N; Wu ZM; McGowan E; Shi J; Hong ZB; Ding CW; Xia P; Di W
    Cancer Sci; 2009 Dec; 100(12):2459-64. PubMed ID: 19769630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
    Mizutani Y; Yoshida O; Miki T; Bonavida B
    Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis.
    Mori S; Murakami-Mori K; Jewett A; Nakamura S; Bonavida B
    Cancer Res; 1996 Apr; 56(8):1874-9. PubMed ID: 8620507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
    Mizutani Y; Wu XX; Yoshida O; Shirasaka T; Bonavida B
    Oncol Rep; 1999; 6(5):979-82. PubMed ID: 10425290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.